LOS ANGELES--(BUSINESS WIRE)-- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and commercialization of molecular diagnostic tests for cancer, announced today the departure of Michael B. McNulty as the Company’s chief operating officer.
During this transition period, Christine Meda, a consultant for the Company, formerly from Roche Diagnostics, with extensive knowledge of the Company and the diagnostics industry, will continue to coordinate business development and commercialization efforts of the Company’s diagnostics.
“We have an operating structure that will continue to oversee our existing activities and our consultant, Christine Meda, will make this transition seamless,” said Kathleen Danenberg, president and CEO of Response Genetics.
About Response Genetics, Inc.
Response Genetics Inc. (“RGI”) is focused on the development and sale of molecular diagnostic tests for cancer. RGI’s technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin-embedded specimens. In addition to diagnostic testing services, the Company generates revenue from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. RGI was founded in 1999 and its principal headquarters are located in Los Angeles, California. For more information, please visit www.responsegenetics.com.
Forward-Looking Statement Notice
Except for the historical information contained herein, this press release and the statements of representatives of RGI related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions, such as the ability of the Company to continue to maintain its growth, the ability of the Company to successfully integrate the roles of operations, strategy and business development, and other statements identified by words such as “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans” or similar expressions.
These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.
CONTACT:
Trout Group
Peter Rahmer, 646-272-8526 (Investors)
or
Fleishman-Hillard
Barry Sudbeck, 415-318-4261 (Media)
KEYWORDS: United States North America California
INDUSTRY KEYWORDS: Health Genetics Oncology
MEDIA:
| Logo |